DE60231570D1 - Synthese von Cyclosporinanalogen - Google Patents

Synthese von Cyclosporinanalogen

Info

Publication number
DE60231570D1
DE60231570D1 DE60231570T DE60231570T DE60231570D1 DE 60231570 D1 DE60231570 D1 DE 60231570D1 DE 60231570 T DE60231570 T DE 60231570T DE 60231570 T DE60231570 T DE 60231570T DE 60231570 D1 DE60231570 D1 DE 60231570D1
Authority
DE
Germany
Prior art keywords
isomers
isa
cyclosporine
derivatives
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231570T
Other languages
English (en)
Inventor
Selvaraj Naicker
Randall W Yatscoff
Robert T Foster
Mark Abel
Seetharaman Jayaraman
Hans-Juergen Mair
Jean-Michel Adam
Bruno Lohri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isotechnika Inc
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Application granted granted Critical
Publication of DE60231570D1 publication Critical patent/DE60231570D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
DE60231570T 2001-10-19 2002-10-17 Synthese von Cyclosporinanalogen Expired - Lifetime DE60231570D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US37059602P 2002-04-05 2002-04-05

Publications (1)

Publication Number Publication Date
DE60231570D1 true DE60231570D1 (de) 2009-04-23

Family

ID=26994746

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2002613115 Expired - Lifetime DE60213115T2 (de) 2001-10-19 2002-10-17 Synthese von cyclosporinanaloga
DE60231570T Expired - Lifetime DE60231570D1 (de) 2001-10-19 2002-10-17 Synthese von Cyclosporinanalogen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2002613115 Expired - Lifetime DE60213115T2 (de) 2001-10-19 2002-10-17 Synthese von cyclosporinanaloga

Country Status (28)

Country Link
US (13) US7141648B2 (de)
EP (2) EP1714977B1 (de)
JP (3) JP4261355B2 (de)
KR (2) KR100982466B1 (de)
CN (1) CN100334106C (de)
AT (2) ATE425178T1 (de)
AU (2) AU2002331509B2 (de)
BR (1) BRPI0213658A8 (de)
CA (1) CA2461740C (de)
CO (1) CO5580836A2 (de)
CY (1) CY1105111T1 (de)
DE (2) DE60213115T2 (de)
DK (2) DK1436321T3 (de)
ES (2) ES2326040T3 (de)
HK (1) HK1062568A1 (de)
HR (2) HRP20040355B1 (de)
IL (3) IL160763A0 (de)
MA (1) MA27293A1 (de)
MX (1) MXPA04003625A (de)
NO (1) NO332459B1 (de)
NZ (1) NZ531944A (de)
PL (2) PL210795B1 (de)
PT (2) PT1714977E (de)
RU (1) RU2321593C9 (de)
SI (1) SI1436321T1 (de)
TN (1) TNSN04068A1 (de)
WO (1) WO2003033526A2 (de)
ZA (1) ZA200402269B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
ES2326040T3 (es) * 2001-10-19 2009-09-29 Isotechnika Inc. Sintesis de analogos de ciclosporina.
MY187182A (en) * 2001-10-19 2021-09-08 Isotechnika Inc Cyclosporine analogue mixtures and their use as immunomodulating agents
EP1603512A2 (de) * 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Neue cyclosporine
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
US20040266669A1 (en) * 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
US7799756B2 (en) 2004-07-29 2010-09-21 Albany Molecular Research, Inc. Processes for stereoselective synthesis of trans ISATX247
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
EP1809656A4 (de) * 2004-09-29 2009-03-25 Amr Technology Inc Cyclosporinalkinanaloga und deren pharmazeutische anwendungen
JP2008515886A (ja) * 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
KR20070100284A (ko) * 2004-12-17 2007-10-10 이소테크니카 인코포레이티드 시클로스포린 유사체의 대사산물
EP1928807A4 (de) * 2005-09-02 2011-05-04 Picobella Llc Onkogene regulatorische rnas für diagnostika und therapeutika
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20070232532A1 (en) * 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
WO2009048929A1 (en) 2007-10-08 2009-04-16 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
EP2151450A1 (de) * 2008-07-29 2010-02-10 Sandoz AG Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
US20130190223A1 (en) * 2008-07-30 2013-07-25 Isotechnika Pharma Inc. Nonimmunosuppressive cyclosporine analogue molecules
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
CA2751210C (en) 2009-01-30 2015-04-21 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
MX338355B (es) 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012079172A1 (en) 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
US20140050728A1 (en) * 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
US10429712B2 (en) 2012-04-20 2019-10-01 View, Inc. Angled bus bar
WO2012145426A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
CN103517707A (zh) 2011-04-29 2014-01-15 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
AU2013267435B2 (en) * 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
EP2705856A1 (de) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Verbindungen zur Behandlung von neurodegenerativen Erkrankungen
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
CN105188666A (zh) 2013-04-01 2015-12-23 阿勒根公司 用于持续的眼内释放的微球药物递送系统
KR20220025909A (ko) 2013-05-03 2022-03-03 셀렉타 바이오사이언시즈, 인크. 면역 관용의 유도를 위한 특정된 약역학적 유효 수명을 갖는 면역억제제 및 항원의 전달
TWI685706B (zh) 2013-06-18 2020-02-21 唯景公司 非矩形之電致變色裝置
EP3038626A4 (de) 2013-08-26 2017-04-19 Enanta Pharmaceuticals, Inc. Cyclosporinanaloga zur prävention oder behandlung von hepatitis-c-infektionen
BR112017001470A2 (pt) 2014-09-07 2018-02-20 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de terapia genética
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
CN107530322B (zh) * 2014-12-17 2021-10-15 维里卡制药有限公司 斑螯素和生物活性斑螯素衍生物的商业上可行的合成
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
CN106554392B (zh) * 2016-11-21 2019-10-25 石家庄中天生物技术有限责任公司 一种高纯度环孢菌素衍生物stg-175的制备方法
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US11584779B2 (en) 2018-10-19 2023-02-21 Teva Pharmaceuticals International Gmbh Solid state forms of voclosporin
EP4201952A1 (de) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Verfahren zur kontrollierten synthese von voclosporin

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525590A (en) * 1894-09-04 canda
US4210581A (en) * 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (de) * 1975-11-04 1979-12-28 Sandoz Ag
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DK25877A (da) 1977-01-21 1978-08-15 Nordisk Insulinlab Fremgangsmaade til udvinding af renset albumin fra blodplasma
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
CH628022A5 (en) 1977-05-10 1982-02-15 Sandoz Ag Process for the preparation of an antibiotic derivative
CH630061A5 (en) 1977-05-10 1982-05-28 Sandoz Ag Process for the preparation of an antibiotic derivative
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
CH630062A5 (en) 1977-05-23 1982-05-28 Sandoz Ag Process for the preparation of an antibiotic derivative
SE448386B (sv) * 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en) * 1979-03-12 1980-05-06 Merck & Co., Inc. Antibiotic A43F
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
AU548156B2 (en) 1980-02-14 1985-11-28 Novartis Ag Cyclo sporin
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
FR2487198A1 (fr) * 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4304641A (en) 1980-11-24 1981-12-08 International Business Machines Corporation Rotary electroplating cell with controlled current distribution
US4384996A (en) 1981-01-09 1983-05-24 Sandoz Ltd. Novel cyclosporins
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4727018A (en) * 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8422253D0 (en) * 1984-09-04 1984-10-10 Sandoz Ltd Organic compounds
WO1986002080A1 (en) 1984-10-04 1986-04-10 Sandoz Ag Monoclonal antibodies to cyclosporings
US5169773A (en) 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
EP0194972B1 (de) 1985-03-11 1992-07-29 Sandoz Ag Cyclosporine
US5047512A (en) * 1985-05-03 1991-09-10 Handschumacher Robert E Immobilized cyclophilin and methods of using such
DE3531597A1 (de) 1985-09-04 1987-03-05 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
CH670644A5 (de) * 1986-12-18 1989-06-30 Lonza Ag
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
US4963683A (en) * 1986-12-18 1990-10-16 Sri International Process for preparing polyoxa tetracyclic compounds
NL194638C (nl) 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US5084441A (en) * 1987-03-04 1992-01-28 Shaw Jack M Acetylated low density lipoproteins: a delivery system to phagocytic cells for stimulating immunologic response and host resistance
US5239057A (en) * 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
EP0283801A3 (de) 1987-03-27 1990-05-30 Abbott Laboratories Fluoreszenz-Polarisations-Test für Cyclosporin A und Metaboliten und verwandte Immunogene und Antikörper
US5427960A (en) * 1987-03-27 1995-06-27 Abbott Laboratories Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ES2059558T3 (es) 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
ATE110784T1 (de) * 1987-06-19 1994-09-15 Sandoz Ag Zyklische peptolide.
GB2206119B (en) 1987-06-22 1990-10-31 Merck & Co Inc A new cyclosporin derivative with modified "8-amino acid"
EP0373260B1 (de) 1987-06-22 1994-03-09 Merck & Co. Inc. Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen
GB8717299D0 (en) * 1987-07-22 1987-08-26 Nat Res Dev Peptides
GB8717300D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
US5227467A (en) * 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
GB2207678A (en) 1987-08-03 1989-02-08 Merck & Co Inc Novel immunosuppressive fluorinated cyclosporin analogs
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5089390A (en) * 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US4866036A (en) * 1987-10-05 1989-09-12 Merck & Co., Inc. Dipeptidyl 5-0,6-0-acyl-2-amino-2-deoxy-D-glucofuranose compositions and methods of use in aids-immunocompromised human hosts
US4868157A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4868155A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4914188A (en) * 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
US5693760A (en) 1988-04-14 1997-12-02 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using HL-60 related lectins
WO1989010351A1 (en) * 1988-04-21 1989-11-02 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis Novel vitamin d analogues
JPH0774799B2 (ja) 1988-04-28 1995-08-09 積水化学工業株式会社 血中成分の測定法
JP3038339B2 (ja) 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
US5013719A (en) * 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
DE3927804A1 (de) 1988-08-24 1990-03-01 Boehringer Ingelheim Kg Verwendung von paf-antagonisten zur behandlung von autoimmunerkrankungen
US5219884A (en) 1988-09-14 1993-06-15 Taito Co., Ltd. Immunosuppressant
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
JPH02124100A (ja) 1988-11-02 1990-05-11 Tonen Corp プロリルイソメラーゼの使用方法
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
AU630901B2 (en) 1988-12-02 1992-11-12 Children's Research Institute Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
US5698448A (en) 1988-12-02 1997-12-16 Soldin; Steven J. Immunosuppressive drug binding proteins and use
AU4958590A (en) 1988-12-05 1990-07-10 Trustees Of Columbia University In The City Of New York, The Novel derivatives of cyclosporine a, antibodies directed thereto and uses thereof
JPH03115228A (ja) 1988-12-09 1991-05-16 G D Searle & Co 免疫抑制剤
US5153327A (en) 1988-12-23 1992-10-06 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
GB2227244A (en) 1989-01-19 1990-07-25 Merck & Co Inc Immunosuppressive fluorinated cyclosporin analogs
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5401731A (en) * 1989-06-29 1995-03-28 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab) Vitamin D analogues
US5068247A (en) 1989-07-07 1991-11-26 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopentanoic acid compounds and their use as immunosuppressants
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5284826A (en) * 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
GB8916901D0 (en) 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
CS277471B6 (cs) 1989-11-16 1993-03-17 Alexandr Rndr Csc Jegorov Deriváty cyklosporinu A
CS277472B6 (cs) 1989-11-16 1993-03-17 Alexandr Rndr Csc Jegorov Způsob výroby derivátů cyklosporinu A
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5591623A (en) * 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5129884A (en) * 1990-01-16 1992-07-14 Dysarz Edward D Trap in barrel one handed retracted intervenous catheter device
US5270419A (en) 1990-01-19 1993-12-14 Nova Pharmaceutical Corporation Polyanhydrides of oligomerized unsaturated aliphatic acids
US5171812A (en) 1990-01-19 1992-12-15 Nova Pharmaceutical Corporation Polyanhydrides of oligomerized unsaturated aliphatic acids
US5214130A (en) * 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
DE4013910A1 (de) 1990-04-26 1991-10-31 Schering Ag Kombinationspraeparat zur immunsuppressiven therapie
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
GB9017890D0 (en) * 1990-08-15 1990-09-26 Leo Pharm Prod Ltd Chemical compounds i
DK0473961T3 (da) * 1990-08-15 1996-07-01 Abbott Lab Immunoassay-reagenser og fremgangsmåde til bestemmelse af cyklosporin
WO1992004055A1 (en) 1990-09-06 1992-03-19 The Australian National University Immunosuppressant composition
DE69124459T3 (de) * 1990-11-02 2001-05-31 Novartis Ag Zyklosporine
ES2181734T3 (es) 1990-11-20 2003-03-01 Dade Behring Marburg Gmbh Ensayo inmunologico de ciclosporina.
ES2078374T3 (es) 1991-04-06 1995-12-16 Dresden Arzneimittel Procedimiento para la produccion por fermentacion y aislamiento de ciclosporina a, y nuevas cepas formadoras de ciclosporina.
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
GB9116470D0 (en) 1991-07-30 1991-09-11 Erba Carlo Spa 2-(imidazol-1-yl)-benzylethylidene-aminoxyalkanoic acid derivatives
WO1993003729A1 (en) 1991-08-12 1993-03-04 Research Corporation Technologies, Inc. N-substituted phenoxazines for treating multidrug resistant cancer cells
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5972630A (en) * 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
US5217586A (en) 1992-01-09 1993-06-08 International Business Machines Corporation Electrochemical tool for uniform metal removal during electropolishing
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
GB9206648D0 (en) * 1992-03-26 1992-05-06 Leo Pharm Prod Ltd Chemical compounds
US5637317A (en) * 1992-05-18 1997-06-10 Dietl; Hans Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same
EP0570829B1 (de) 1992-05-18 2001-04-25 CicloMulsion AG Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
HU213553B (en) * 1992-05-25 1997-07-28 Biogal Gyogyszergyar Process for isolating of cyclosporin-a
WO1993025533A1 (en) 1992-06-05 1993-12-23 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
EP0647625A1 (de) * 1992-06-23 1995-04-12 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Neue antibiotica mit immunosuppresiver aktivität, delaminomycine und deren herstellung
GB9214202D0 (en) * 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
EP0578616A3 (en) 1992-07-09 1994-06-01 Sandoz Ltd Cylosporin synthetase
CZ278863B6 (en) 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
GB9220439D0 (en) 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
US5318895A (en) 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
US5298523A (en) * 1992-12-14 1994-03-29 Harbor Branch Oceanographic Institution, Inc. Method for treating transplant patients using mycalamide compounds
GB9226877D0 (en) * 1992-12-23 1993-02-17 Leo Pharm Prod Ltd Chemical compounds
CA2086267A1 (en) 1992-12-24 1994-06-25 Argyrios Margaritis Cyclosporin derivatives and derivative conjugates
FI92334C (fi) * 1992-12-30 1994-10-25 Leiras Oy Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
US5393669A (en) * 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
CA2155728C (en) * 1993-02-12 2000-04-25 Gerald R. Crabtree Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5468772A (en) 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
CZ291237B6 (cs) 1993-04-20 2003-01-15 Novartis Ag Farmaceutický přípravek pro orální podání obsahující cyklosporin A
EP0696323A1 (de) 1993-04-23 1996-02-14 Novartis AG Rekombinante alanin racemase und gadph aus tolypocladium niveum
JPH09500103A (ja) * 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド シクロヘキサペプチジルアミノアルキルエーテル
DE4338086A1 (de) 1993-11-08 1995-05-11 Dietl Hans Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur oralen Applikation sowie Verfahren zu ihrer Herstellung
WO1995005372A1 (fr) 1993-08-13 1995-02-23 Banyu Pharmaceutical Co., Ltd. Derive de cyclopentane a activite antagoniste de l'endotheline
DE69426698T2 (de) 1993-08-18 2001-08-16 Banyu Pharma Co Ltd Kondensierte heteroaromatische cyclopentenderivate mit endothelin-antagonistischer aktivität
US5421987A (en) 1993-08-30 1995-06-06 Tzanavaras; George Precision high rate electroplating cell and method
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
DE59409377D1 (de) 1993-10-22 2000-06-29 Hexal Ag Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
JPH07278187A (ja) 1994-04-07 1995-10-24 Nippon Shinyaku Co Ltd シクロスポリン類のリン酸エステル誘導体及び医薬組成物
US5798386A (en) 1994-08-03 1998-08-25 Cell Therapeutics, Inc. Angiogenic lipid formulations
US5639852A (en) 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5948693A (en) 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
US5567300A (en) 1994-09-02 1996-10-22 Ibm Corporation Electrochemical metal removal technique for planarization of surfaces
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
DE4433101A1 (de) 1994-09-16 1996-03-21 Bauer Kurt Heinz Prof Dr Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren
HU215966B (hu) 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
US5648376A (en) * 1995-01-19 1997-07-15 Pharmagenesis, Inc. Immunosuppressant diterpene compound
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5668734A (en) 1995-04-10 1997-09-16 The Uab Research Foundation Method for analyzing 2D transferred noesy spectra of molecules undergoing multistate conformational exchange
JPH11504028A (ja) 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
JP3934705B2 (ja) 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5624902A (en) * 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
DE19521974A1 (de) 1995-06-16 1996-12-19 Hexal Pharmaforschung Gmbh Pharmazeutische Zubereitung mit Cyclosporin A
IL122754A (en) 1995-07-17 2001-10-31 Chem Ag C History of cyclosporine, their preparation and the pharmaceutical preparations containing them
JPH0978187A (ja) 1995-09-07 1997-03-25 Daido Steel Co Ltd メッキ用快削鋼
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CA2248192A1 (en) 1996-03-12 1997-09-18 Picower Institute For Medical Research Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity
US5840305A (en) 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
DE19611094C2 (de) 1996-03-21 1999-06-17 Dresden Arzneimittel Verfahren zur Reinigung von Cyclosporin A und/oder verwandten Cyclosporinen aus einem Cyclosporin-haltigen Rohextrakt unter Anwendung chromatographischer Verfahren mit Kieselgel als Adsorbens
AUPN880396A0 (en) 1996-03-21 1996-04-18 Fremantle Hospital Animal model for transplantation
JPH1029979A (ja) 1996-04-12 1998-02-03 Ajinomoto Co Inc 新規ピリジン誘導体
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
US5709797A (en) * 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins
US5747330A (en) * 1996-06-05 1998-05-05 Poli Industria Chimica Antibiotic producing microbe
JP2001523221A (ja) 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
GB9619894D0 (en) 1996-09-24 1996-11-06 Celltech Therapeutics Ltd Pharmaceutical products
CA2266622C (en) 1996-09-27 2006-08-15 Hyal Pharmaceutical Corporation Hyaluronic drug delivery system
EP0948321B1 (de) 1996-12-12 2003-10-22 Dds Drug Delivery Service Gesellschaft Zur Förderung Der Forschung In Pharmazeutischer Technologie Und Biopharmazie Mbh Zubereitung in form eines wahlweise wirkstoffhaltigen matrixmaterial-hilfsstoff compounds
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
US5843520A (en) 1997-01-13 1998-12-01 Vanguard International Semiconductor Corporation Substrate clamp design for minimizing substrate to clamp sticking during thermal processing of thermally flowable layers
JPH10251137A (ja) 1997-03-14 1998-09-22 Advanced Sukin Res Kenkyusho:Kk 光線過敏症抑制剤
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
WO1999010374A1 (en) 1997-08-26 1999-03-04 Wisconsin Alumni Research Foundation Cyclosporin a conjugates and uses therefor
NZ502362A (en) 1997-10-08 2001-05-25 Isotechnika Inc Deuterated cyclosporine A derivatives and their use as immunomodulating agents
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
FR2772768B1 (fr) * 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
US6706691B1 (en) 1998-07-15 2004-03-16 Board Of Regents, The University Of Texas System Immunosupportive drug sparing diet
US6183611B1 (en) 1998-07-17 2001-02-06 Cutek Research, Inc. Method and apparatus for the disposal of processing fluid used to deposit and/or remove material on a substrate
US6187152B1 (en) 1998-07-17 2001-02-13 Cutek Research, Inc. Multiple station processing chamber and method for depositing and/or removing material on a substrate
FI110094B (fi) 1999-09-10 2002-11-29 Ecospec Ltd Oy Menetelmä maanparannusaineen valmistamiseksi
CA2383233C (en) 1999-09-21 2010-06-08 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
EP1408930A1 (de) 1999-10-20 2004-04-21 Vesifact Ag Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen
US6613793B2 (en) 2001-07-02 2003-09-02 Dabur Research Foundation Anticancer activity of imino acid conjugates or methylglyoxal
ES2326040T3 (es) * 2001-10-19 2009-09-29 Isotechnika Inc. Sintesis de analogos de ciclosporina.
MY187182A (en) 2001-10-19 2021-09-08 Isotechnika Inc Cyclosporine analogue mixtures and their use as immunomodulating agents
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
EP1603512A2 (de) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Neue cyclosporine

Also Published As

Publication number Publication date
US20050192214A1 (en) 2005-09-01
JP2010280710A (ja) 2010-12-16
ATE425178T1 (de) 2009-03-15
IL160763A (en) 2009-11-18
EP1714977A3 (de) 2007-01-10
JP4887469B2 (ja) 2012-02-29
AU2010206069A1 (en) 2010-08-19
EP1436321A2 (de) 2004-07-14
JP2005516893A (ja) 2005-06-09
CA2461740A1 (en) 2003-04-24
US7141648B2 (en) 2006-11-28
AU2002331509B2 (en) 2007-12-06
TNSN04068A1 (en) 2006-06-01
EP1436321B1 (de) 2006-07-12
KR100982466B1 (ko) 2010-09-16
NO332459B1 (no) 2012-09-24
US10472394B2 (en) 2019-11-12
MA27293A1 (fr) 2005-05-02
PL392749A1 (pl) 2011-01-03
CN1571795A (zh) 2005-01-26
EP1714977B1 (de) 2009-03-11
HRP20040355B1 (hr) 2012-10-31
US20030212249A1 (en) 2003-11-13
RU2321593C9 (ru) 2008-06-20
JP4261355B2 (ja) 2009-04-30
DE60213115D1 (en) 2006-08-24
KR20050037417A (ko) 2005-04-21
CY1105111T1 (el) 2010-03-03
US20100311944A1 (en) 2010-12-09
US7332472B2 (en) 2008-02-19
KR20090130195A (ko) 2009-12-18
US9765119B2 (en) 2017-09-19
BRPI0213658A8 (pt) 2016-12-06
US20130078280A1 (en) 2013-03-28
ES2326040T3 (es) 2009-09-29
NZ531944A (en) 2006-03-31
US20070087963A1 (en) 2007-04-19
US20160075741A1 (en) 2016-03-17
PT1436321E (pt) 2006-10-31
CO5580836A2 (es) 2005-11-30
PL370772A1 (en) 2005-05-30
JP5396571B2 (ja) 2014-01-22
RU2004110940A (ru) 2005-06-27
US20140142277A1 (en) 2014-05-22
US20170362277A1 (en) 2017-12-21
SI1436321T1 (sl) 2006-12-31
WO2003033526A2 (en) 2003-04-24
US20100062976A1 (en) 2010-03-11
CN100334106C (zh) 2007-08-29
USRE48226E1 (en) 2020-09-29
ZA200402269B (en) 2005-05-25
DE60213115T2 (de) 2007-02-01
PL210841B1 (pl) 2012-03-30
RU2321593C2 (ru) 2008-04-10
US20140370082A1 (en) 2014-12-18
IL186140A (en) 2012-02-29
EP1436321B9 (de) 2008-11-12
US20030139326A1 (en) 2003-07-24
CA2461740C (en) 2013-02-12
KR101006206B1 (ko) 2011-01-07
MXPA04003625A (es) 2004-12-02
PL210795B1 (pl) 2012-03-30
JP2009046515A (ja) 2009-03-05
IL186140A0 (en) 2008-01-20
PT1714977E (pt) 2009-06-23
ATE332917T1 (de) 2006-08-15
EP1714977A2 (de) 2006-10-25
HRP20070058B1 (hr) 2014-05-23
HRP20040355A2 (en) 2005-04-30
BR0213658A (pt) 2004-10-26
IL160763A0 (en) 2004-08-31
DK1436321T3 (da) 2006-11-13
US6998385B2 (en) 2006-02-14
NO20042031L (no) 2004-05-19
WO2003033526A3 (en) 2004-02-12
ES2266564T3 (es) 2007-03-01
DK1714977T3 (da) 2009-07-06
HRP20070058A2 (en) 2008-09-30
US20080171850A1 (en) 2008-07-17
HK1062568A1 (en) 2004-11-12

Similar Documents

Publication Publication Date Title
ATE332917T1 (de) Synthese von cyclosporin-analogen
MY187182A (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
ATE334654T1 (de) Vor uv-strahlen schützende zusammensetzungen
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
HK1039034A1 (en) Agents for controlling plant pests.
ATE245435T1 (de) Totalsynthese des amino hip analogen von didemnin a
MA27862A1 (fr) Composition pharmaceutique
YU33204A (sh) Sinteza analoga ciklosporina
YU33004A (sh) Smeša analoga ciklosporina i njihova upotreba u svojstvu imunomodulatornih supstanci
HUP0004799A2 (hu) Elektrolitelegyek alkalmazása komplexképző szerként
UY27523A1 (es) Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica
MY131116A (en) Olefin polymerization catalyst composition comprising group 13 amide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition